Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 7 pages
Data source: Published sources
Topics:
Nicholas Piramal India Limited; Ajay Piramal; Joint venture; Mergers & acquisitions (M&A); Research and development (R&D); Growth strategy; Indian pharmaceutical industry; Blockbuster drugs; GlaxoSmithKline; Rhone Poulenc; Generic competition; Big Pharma; Patents and patented drugs; Food and drug administration (FDA); 1970 Indian Patent Act
Share a link:
https://casecent.re/p/19722
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
As India moves towards 2005 product patent regime, many Indian firms are scouting for buyouts and acquisitions of the US and European companies. Ranbaxy, Dr Reddy''s, Wockhardt and others are in the front for acquiring such companies. Nicholas Piramal India Ltd, (NPIL) on the other hand is doing exactly the opposite. The company is acquiring more Indian than western firms. In the Indian pharma industry, NPIL has made more acquisitions than any other firm. In 2003, NPIL ranked third in the Indian pharmaceutical industry with a market share of 4.4%, next only to market leader GlaxoSmithKline (5.7%) and Ranbaxy (4.7%). By adopting the strategy of mergers and acquisitions (M&As), it intends to become the top player in the Indian pharma industry. The case offers rich insights into NPIL''s business strategy of acquiring firms and there by becoming a leader in the Indian pharmaceutical industry.
About
Abstract
As India moves towards 2005 product patent regime, many Indian firms are scouting for buyouts and acquisitions of the US and European companies. Ranbaxy, Dr Reddy''s, Wockhardt and others are in the front for acquiring such companies. Nicholas Piramal India Ltd, (NPIL) on the other hand is doing exactly the opposite. The company is acquiring more Indian than western firms. In the Indian pharma industry, NPIL has made more acquisitions than any other firm. In 2003, NPIL ranked third in the Indian pharmaceutical industry with a market share of 4.4%, next only to market leader GlaxoSmithKline (5.7%) and Ranbaxy (4.7%). By adopting the strategy of mergers and acquisitions (M&As), it intends to become the top player in the Indian pharma industry. The case offers rich insights into NPIL''s business strategy of acquiring firms and there by becoming a leader in the Indian pharmaceutical industry.